Your browser doesn't support javascript.
loading
Opsoclonus-myoclonus syndrome associated with pancreatic neuroendocrine tumor: a case report.
Reinecke, Raphael; Reiländer, Annemarie; Seiler, Alexander; Koch, Christine; Voss, Martin.
Afiliação
  • Reinecke R; Department of Neurology, Goethe University Frankfurt, Frankfurt am Main, Germany. raphael.reinecke@kgu.de.
  • Reiländer A; Dr. Senckenberg Institute of Neurooncology, Goethe University Frankfurt, Frankfurt am Main, Germany. raphael.reinecke@kgu.de.
  • Seiler A; Department of Neurology, Goethe University Frankfurt, Frankfurt am Main, Germany.
  • Koch C; Department of Neurology, Goethe University Frankfurt, Frankfurt am Main, Germany.
  • Voss M; Department of Gastroenterology, Hepatology and Endocrinology, Goethe University Frankfurt, Frankfurt am Main, Germany.
BMC Neurol ; 22(1): 507, 2022 Dec 30.
Article em En | MEDLINE | ID: mdl-36581905
ABSTRACT

BACKGROUND:

Opsoclonus-myoclonus syndrome (OMS) is a rare, immune-mediated neurological disorder. In adults, the pathogenesis can be idiopathic, post-infectious or paraneoplastic, the latter etiology belonging to the ever-expanding group of defined paraneoplastic neurological syndromes (PNS). In contrast to other phenotypes of PNS, OMS cannot be ascribed to a single pathogenic autoantibody. Here, we report the first detailed case of paraneoplastic, antibody-negative OMS occurring in association with a pancreatic neuroendocrine tumor (pNET). CASE PRESENTATION A 33-year-old female presented with a two-week history of severe ataxia of stance and gait, dysarthria, head tremor, myoclonus of the extremities and opsoclonus. Her past medical history was notable for a metastatic pancreatic neuroendocrine tumor, and she was subsequently diagnosed with paraneoplastic opsoclonus-myoclonus syndrome. Further workup did not reveal a paraneoplastic autoantibody. She responded well to plasmapheresis, as she was refractory to the first-line therapy with corticosteroids.

CONCLUSIONS:

This case expands current knowledge on tumors associated with paraneoplastic opsoclonus-myoclonus syndrome and the age group in which it can occur. It further adds evidence to the effectiveness of plasmapheresis in severe cases of opsoclonus-myoclonus syndrome with a lack of response to first-line therapy.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Tumores Neuroendócrinos / Síndrome de Opsoclonia-Mioclonia Tipo de estudo: Diagnostic_studies / Etiology_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: BMC Neurol Assunto da revista: NEUROLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Tumores Neuroendócrinos / Síndrome de Opsoclonia-Mioclonia Tipo de estudo: Diagnostic_studies / Etiology_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: BMC Neurol Assunto da revista: NEUROLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha